Capital Advisors Ltd’s Adverum Biotechnologies ADVM Stock Holding History

Capital Advisors Ltd’s Portfolio ADVM Stock Details ADVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-59	Closed	-$1K	–	875
2021 Q4	$1K	Buy	+59	New	+$1.18K	﹤0.01%	605

Other funds holding ADVM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

SFI

Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital Advisors Ltd's ADVM Position: Q1 2022 in Review

Capital Advisors Ltd sold out of Adverum Biotechnologies (ADVM) in Q1 2022, closing a stake of 59 shares — an estimated $1K sold.

Capital Advisors Ltd first reported a position in ADVM in Q4 2021 and held it in 1 quarter. The position peaked at $1K in Q4 2021. 92 funds tracked by Wall St. Rank hold ADVM as of Q1 2022.

Capital Advisors Ltd reported no remaining Adverum Biotechnologies position as of Q1 2022 after selling out during the quarter.
Capital Advisors Ltd sold 59 Adverum Biotechnologies shares in Q1 2022, an estimated $1K.
Capital Advisors Ltd first reported a position in Adverum Biotechnologies in Q4 2021 and held it in 1 quarter.
Capital Advisors Ltd's Adverum Biotechnologies position peaked at $1K in Q4 2021.
92 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q1 2022.

Based on Capital Advisors Ltd's 13F filing for Q1 2022, filed 9 May 2022.